love_gundu22
Praveen Gurwani
Granules India (GRANUL)
By Raghvendra Kumar PICK OF THE WEEK
Granules India is set to become an integrated player by Jan 2007 when its tablet- manufacturing unit gets ready for commercial production. We rate the stock an OUTPERFORMER with a price target of Rs 130 over 15-18 months.
Background
Granules India started operations in April 1991 as an exporter of bulk drugs. In Aug 1994, it acquired a group company, Triton Laboratories (TL), from which it was procuring drugs for exports. It completed the on-going project to manufacture bulk drugs like folic acid, salbutamol sulphate, brom pheniramine maleate and direct compression (DC) of paracetamol through the process of granulation. Today, Granules manufactures several active pharmaceutical ingredients (APIs) and pharmaceutical formulations intermediates (PFIs). PFIs are pre-processed blends of single or multiple APIs, ready to be compressed into tablets or to be filled in capsules. They represent an intermediate stage between APIs and formulations.
The company has strong capabilities to manufacture PFIs through non-infringing processes. It has emerged as a completely integrated and dependable pharmaceutical manufacturing outsourcing company. It markets its PFIs under the brand name of CompressoTM for over 40 countries, including the US, Canada, Mexico, Europe, Australia, New Zealand, South America and South Africa.
to know more open the attachment below.......................
HAPPY INVESTING.:bump:
By Raghvendra Kumar PICK OF THE WEEK
Granules India is set to become an integrated player by Jan 2007 when its tablet- manufacturing unit gets ready for commercial production. We rate the stock an OUTPERFORMER with a price target of Rs 130 over 15-18 months.
Background
Granules India started operations in April 1991 as an exporter of bulk drugs. In Aug 1994, it acquired a group company, Triton Laboratories (TL), from which it was procuring drugs for exports. It completed the on-going project to manufacture bulk drugs like folic acid, salbutamol sulphate, brom pheniramine maleate and direct compression (DC) of paracetamol through the process of granulation. Today, Granules manufactures several active pharmaceutical ingredients (APIs) and pharmaceutical formulations intermediates (PFIs). PFIs are pre-processed blends of single or multiple APIs, ready to be compressed into tablets or to be filled in capsules. They represent an intermediate stage between APIs and formulations.
The company has strong capabilities to manufacture PFIs through non-infringing processes. It has emerged as a completely integrated and dependable pharmaceutical manufacturing outsourcing company. It markets its PFIs under the brand name of CompressoTM for over 40 countries, including the US, Canada, Mexico, Europe, Australia, New Zealand, South America and South Africa.
to know more open the attachment below.......................
HAPPY INVESTING.:bump: